CA2610873C - Tetrahydroquinolines and their use as modulators of metabotropic glutamate receptors - Google Patents

Info

Publication number

CA2610873C

CA2610873C CA2610873A CA2610873A CA2610873C CA 2610873 C CA2610873 C CA 2610873C CA 2610873 A CA2610873 A CA 2610873A CA 2610873 A CA2610873 A CA 2610873A CA 2610873 C CA2610873 C CA 2610873C

Authority

CA

Canada

Prior art keywords

quinolin

dihydro

dimethyl

ylethynyl

phenylethynyl

Prior art date

2005-08-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 102000016193 Metabotropic glutamate receptors Human genes 0.000 title abstract description 23
• 108010010914 Metabotropic glutamate receptors Proteins 0.000 title abstract description 23
• 150000003530 tetrahydroquinolines Chemical class 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 183
• -1 ethynyl-substituted tetrahydroquinolinone Chemical class 0.000 claims abstract description 68
• 150000003839 salts Chemical class 0.000 claims abstract description 26
• 230000002265 prevention Effects 0.000 claims abstract description 8
• 230000001154 acute effect Effects 0.000 claims abstract description 7
• 230000001684 chronic effect Effects 0.000 claims abstract description 7
• 229910052731 fluorine Inorganic materials 0.000 claims description 63
• 239000000460 chlorine Chemical group 0.000 claims description 61
• 229910052801 chlorine Inorganic materials 0.000 claims description 61
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 52
• 125000001424 substituent group Chemical group 0.000 claims description 47
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 40
• 239000011737 fluorine Substances 0.000 claims description 40
• 125000001246 bromo group Chemical group Br* 0.000 claims description 39
• 125000001153 fluoro group Chemical group F* 0.000 claims description 38
• 125000003118 aryl group Chemical group 0.000 claims description 36
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
• 125000005842 heteroatom Chemical group 0.000 claims description 30
• 239000003814 drug Substances 0.000 claims description 29
• 201000010099 disease Diseases 0.000 claims description 26
• 125000001072 heteroaryl group Chemical group 0.000 claims description 26
• 239000004480 active ingredient Substances 0.000 claims description 25
• 229910052739 hydrogen Inorganic materials 0.000 claims description 25
• 239000001257 hydrogen Substances 0.000 claims description 24
• 125000004076 pyridyl group Chemical group 0.000 claims description 24
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 24
• 229910052794 bromium Inorganic materials 0.000 claims description 23
• 206010012289 Dementia Diseases 0.000 claims description 22
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
• 125000002541 furyl group Chemical group 0.000 claims description 22
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
• 125000000842 isoxazolyl group Chemical group 0.000 claims description 22
• 125000002757 morpholinyl group Chemical group 0.000 claims description 22
• 125000003386 piperidinyl group Chemical group 0.000 claims description 22
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 22
• 125000000335 thiazolyl group Chemical group 0.000 claims description 22
• 125000001544 thienyl group Chemical group 0.000 claims description 22
• 125000002883 imidazolyl group Chemical group 0.000 claims description 21
• 125000001715 oxadiazolyl group Chemical group 0.000 claims description 21
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
• 229910052740 iodine Inorganic materials 0.000 claims description 20
• 125000002971 oxazolyl group Chemical group 0.000 claims description 20
• 239000008194 pharmaceutical composition Substances 0.000 claims description 20
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 19
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
• 125000002393 azetidinyl group Chemical group 0.000 claims description 18
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 18
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 18
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 17
• 201000006417 multiple sclerosis Diseases 0.000 claims description 16
• 208000023105 Huntington disease Diseases 0.000 claims description 15
• 241001465754 Metazoa Species 0.000 claims description 15
• 208000008589 Obesity Diseases 0.000 claims description 15
• 229910052757 nitrogen Inorganic materials 0.000 claims description 15
• 235000020824 obesity Nutrition 0.000 claims description 15
• 208000010877 cognitive disease Diseases 0.000 claims description 14
• 229940079593 drug Drugs 0.000 claims description 14
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 13
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 13
• 208000018737 Parkinson disease Diseases 0.000 claims description 13
• 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 13
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
• 241000282414 Homo sapiens Species 0.000 claims description 12
• 239000000556 agonist Substances 0.000 claims description 12
• 150000004677 hydrates Chemical class 0.000 claims description 12
• 230000003287 optical effect Effects 0.000 claims description 12
• 239000012453 solvate Substances 0.000 claims description 12
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 11
• 208000019901 Anxiety disease Diseases 0.000 claims description 11
• 208000024827 Alzheimer disease Diseases 0.000 claims description 10
• 206010010904 Convulsion Diseases 0.000 claims description 10
• 208000004454 Hyperalgesia Diseases 0.000 claims description 10
• 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims description 10
• 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 10
• 208000006673 asthma Diseases 0.000 claims description 10
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
• 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 10
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 10
• 230000036461 convulsion Effects 0.000 claims description 10
• 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 10
• 208000002551 irritable bowel syndrome Diseases 0.000 claims description 10
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
• 210000000111 lower esophageal sphincter Anatomy 0.000 claims description 10
• 208000024714 major depressive disease Diseases 0.000 claims description 10
• 229910052760 oxygen Inorganic materials 0.000 claims description 10
• 239000001301 oxygen Substances 0.000 claims description 10
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
• 208000024891 symptom Diseases 0.000 claims description 10
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
• 201000000980 schizophrenia Diseases 0.000 claims description 9
• 239000000126 substance Substances 0.000 claims description 9
• 229910052717 sulfur Inorganic materials 0.000 claims description 9
• 239000011593 sulfur Substances 0.000 claims description 9
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
• 208000028698 Cognitive impairment Diseases 0.000 claims description 8
• 206010012335 Dependence Diseases 0.000 claims description 8
• 208000001914 Fragile X syndrome Diseases 0.000 claims description 8
• 230000037410 cognitive enhancement Effects 0.000 claims description 8
• 206010015037 epilepsy Diseases 0.000 claims description 8
• VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 8
• 208000004296 neuralgia Diseases 0.000 claims description 8
• 208000021722 neuropathic pain Diseases 0.000 claims description 8
• 208000019906 panic disease Diseases 0.000 claims description 8
• 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
• XNVDHQYDSCNZML-UHFFFAOYSA-N 2-[2-(2-phenyl-1,3-thiazol-5-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC(S1)=CN=C1C1=CC=CC=C1 XNVDHQYDSCNZML-UHFFFAOYSA-N 0.000 claims description 7
• 208000009205 Tinnitus Diseases 0.000 claims description 7
• 208000035475 disorder Diseases 0.000 claims description 7
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 230000004112 neuroprotection Effects 0.000 claims description 7
• 231100000886 tinnitus Toxicity 0.000 claims description 7
• 208000002193 Pain Diseases 0.000 claims description 6
• 208000028017 Psychotic disease Diseases 0.000 claims description 6
• 230000007278 cognition impairment Effects 0.000 claims description 6
• 208000027061 mild cognitive impairment Diseases 0.000 claims description 6
• 238000010992 reflux Methods 0.000 claims description 6
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 5
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 5
• 206010065040 AIDS dementia complex Diseases 0.000 claims description 5
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
• 206010003805 Autism Diseases 0.000 claims description 5
• 208000020706 Autistic disease Diseases 0.000 claims description 5
• 208000020925 Bipolar disease Diseases 0.000 claims description 5
• 241001115070 Bornavirus Species 0.000 claims description 5
• 206010006550 Bulimia nervosa Diseases 0.000 claims description 5
• 201000010374 Down Syndrome Diseases 0.000 claims description 5
• 206010052804 Drug tolerance Diseases 0.000 claims description 5
• 208000012661 Dyskinesia Diseases 0.000 claims description 5
• 208000014094 Dystonic disease Diseases 0.000 claims description 5
• 208000030814 Eating disease Diseases 0.000 claims description 5
• 208000020564 Eye injury Diseases 0.000 claims description 5
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
• 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
• 208000010412 Glaucoma Diseases 0.000 claims description 5
• 208000032612 Glial tumor Diseases 0.000 claims description 5
• 206010018338 Glioma Diseases 0.000 claims description 5
• 208000031886 HIV Infections Diseases 0.000 claims description 5
• 206010019196 Head injury Diseases 0.000 claims description 5
• 208000010496 Heart Arrest Diseases 0.000 claims description 5
• 208000035154 Hyperesthesia Diseases 0.000 claims description 5
• 208000013016 Hypoglycemia Diseases 0.000 claims description 5
• 206010021143 Hypoxia Diseases 0.000 claims description 5
• 206010065390 Inflammatory pain Diseases 0.000 claims description 5
• 208000006264 Korsakoff syndrome Diseases 0.000 claims description 5
• 201000008197 Laryngitis Diseases 0.000 claims description 5
• 208000019693 Lung disease Diseases 0.000 claims description 5
• 208000021891 Micturition disease Diseases 0.000 claims description 5
• 208000019695 Migraine disease Diseases 0.000 claims description 5
• 208000016285 Movement disease Diseases 0.000 claims description 5
• 208000001089 Multiple system atrophy Diseases 0.000 claims description 5
• 208000007101 Muscle Cramp Diseases 0.000 claims description 5
• 208000008238 Muscle Spasticity Diseases 0.000 claims description 5
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 208000001294 Nociceptive Pain Diseases 0.000 claims description 5
• 102000029797 Prion Human genes 0.000 claims description 5
• 108091000054 Prion Proteins 0.000 claims description 5
• 208000003251 Pruritus Diseases 0.000 claims description 5
• 206010067171 Regurgitation Diseases 0.000 claims description 5
• 206010057190 Respiratory tract infections Diseases 0.000 claims description 5
• 208000005793 Restless legs syndrome Diseases 0.000 claims description 5
• 208000017442 Retinal disease Diseases 0.000 claims description 5
• 206010038923 Retinopathy Diseases 0.000 claims description 5
• 208000005392 Spasm Diseases 0.000 claims description 5
• 208000034799 Tauopathies Diseases 0.000 claims description 5
• 208000000323 Tourette Syndrome Diseases 0.000 claims description 5
• 208000016620 Tourette disease Diseases 0.000 claims description 5
• 206010044688 Trisomy 21 Diseases 0.000 claims description 5
• 206010046543 Urinary incontinence Diseases 0.000 claims description 5
• 201000004810 Vascular dementia Diseases 0.000 claims description 5
• 206010047700 Vomiting Diseases 0.000 claims description 5
• 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 5
• 206010053552 allodynia Diseases 0.000 claims description 5
• 229940025084 amphetamine Drugs 0.000 claims description 5
• 230000036506 anxiety Effects 0.000 claims description 5
• 201000009243 chronic laryngitis Diseases 0.000 claims description 5
• 229960003920 cocaine Drugs 0.000 claims description 5
• 235000014632 disordered eating Nutrition 0.000 claims description 5
• 201000006549 dyspepsia Diseases 0.000 claims description 5
• 208000010118 dystonia Diseases 0.000 claims description 5
• 210000003027 ear inner Anatomy 0.000 claims description 5
• 210000001652 frontal lobe Anatomy 0.000 claims description 5
• 210000003128 head Anatomy 0.000 claims description 5
• 208000007386 hepatic encephalopathy Diseases 0.000 claims description 5
• 230000007954 hypoxia Effects 0.000 claims description 5
• 208000015181 infectious disease Diseases 0.000 claims description 5
• 208000014674 injury Diseases 0.000 claims description 5
• 208000028867 ischemia Diseases 0.000 claims description 5
• 208000002780 macular degeneration Diseases 0.000 claims description 5
• 206010027599 migraine Diseases 0.000 claims description 5
• 230000004065 mitochondrial dysfunction Effects 0.000 claims description 5
• 208000005264 motor neuron disease Diseases 0.000 claims description 5
• 208000018360 neuromuscular disease Diseases 0.000 claims description 5
• 229960002715 nicotine Drugs 0.000 claims description 5
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 5
• 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims description 5
• 229940127240 opiate Drugs 0.000 claims description 5
• 229940005483 opioid analgesics Drugs 0.000 claims description 5
• 230000009984 peri-natal effect Effects 0.000 claims description 5
• 230000002980 postoperative effect Effects 0.000 claims description 5
• 230000001823 pruritic effect Effects 0.000 claims description 5
• 208000019116 sleep disease Diseases 0.000 claims description 5
• 208000018198 spasticity Diseases 0.000 claims description 5
• 208000020431 spinal cord injury Diseases 0.000 claims description 5
• 208000011580 syndromic disease Diseases 0.000 claims description 5
• 230000008733 trauma Effects 0.000 claims description 5
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
• 210000001635 urinary tract Anatomy 0.000 claims description 5
• 230000002792 vascular Effects 0.000 claims description 5
• 230000009385 viral infection Effects 0.000 claims description 5
• 230000008673 vomiting Effects 0.000 claims description 5
• QLVQNCUDTHFEPO-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one;2-[2-(3-methoxyphenyl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CC(F)=C1.COC1=CC=CC(C#CC=2N=C3CC(C)(C)CC(=O)C3=CC=2)=C1 QLVQNCUDTHFEPO-UHFFFAOYSA-N 0.000 claims description 4
• RRTIHDTYZOYWHA-UHFFFAOYSA-N 2-[2-(4-fluoro-5-pyridin-3-yl-1,3-oxazol-2-yl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(O1)=NC(F)=C1C1=CC=CN=C1 RRTIHDTYZOYWHA-UHFFFAOYSA-N 0.000 claims description 4
• PQIPQTFRKQAFKG-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(1,3-oxazol-5-yl)ethynyl]-6,8-dihydroquinolin-5-one;2-[2-(2-phenyl-1,3-oxazol-5-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CN=CO1.C=1C=C2C(=O)CCCC2=NC=1C#CC(O1)=CN=C1C1=CC=CC=C1 PQIPQTFRKQAFKG-UHFFFAOYSA-N 0.000 claims description 4
• POXKAIBLBPVHSW-UHFFFAOYSA-N BrC=1C=C(C=CC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C.ClC=1C=C(C=CC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C Chemical compound BrC=1C=C(C=CC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C.ClC=1C=C(C=CC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C POXKAIBLBPVHSW-UHFFFAOYSA-N 0.000 claims description 4
• NETJLSVFWHJZNP-UHFFFAOYSA-N C1(=CC(=CC=C1)C#CC1=NC=2CCCC(C2C=C1)=O)C.N1=CC(=CC=C1)C#CC1=NC=2CCCC(C2C=C1)=O.C1(=CC=CC=C1)C#CC1=NC=2CCCC(C2C=C1)=O Chemical compound C1(=CC(=CC=C1)C#CC1=NC=2CCCC(C2C=C1)=O)C.N1=CC(=CC=C1)C#CC1=NC=2CCCC(C2C=C1)=O.C1(=CC=CC=C1)C#CC1=NC=2CCCC(C2C=C1)=O NETJLSVFWHJZNP-UHFFFAOYSA-N 0.000 claims description 4
• AHXXHJCLJTYXSP-UHFFFAOYSA-N CC1(CC(C=2C=CC(=NC2C1)C#CC=1C=NC=CC1)=O)C.O1C=NC=C1C#CC1=NC=2CCCC(C2C=C1)=O.S1C=NC=C1C#CC1=NC=2CCCC(C2C=C1)=O Chemical compound CC1(CC(C=2C=CC(=NC2C1)C#CC=1C=NC=CC1)=O)C.O1C=NC=C1C#CC1=NC=2CCCC(C2C=C1)=O.S1C=NC=C1C#CC1=NC=2CCCC(C2C=C1)=O AHXXHJCLJTYXSP-UHFFFAOYSA-N 0.000 claims description 4
• YCUZIWUOCSLOOY-UHFFFAOYSA-N FC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O.COC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O.OC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O Chemical compound FC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O.COC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O.OC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O YCUZIWUOCSLOOY-UHFFFAOYSA-N 0.000 claims description 4
• UWBIMCLHNNQQQB-UHFFFAOYSA-N OC=1C=C(C=CC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C.CC1(CC(C=2C=CC(=NC2C1)C#CC=1C=C(C=CC1)C)=O)C Chemical compound OC=1C=C(C=CC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C.CC1(CC(C=2C=CC(=NC2C1)C#CC=1C=C(C=CC1)C)=O)C UWBIMCLHNNQQQB-UHFFFAOYSA-N 0.000 claims description 4
• 230000000897 modulatory effect Effects 0.000 claims description 4
• 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 4
• PEMXOKOYRLFDDT-UHFFFAOYSA-N 2-(2-pyridin-2-ylethynyl)-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=CC=CC=N1 PEMXOKOYRLFDDT-UHFFFAOYSA-N 0.000 claims description 3
• FROMKVSMGOVTQO-UHFFFAOYSA-N 2-[2-(4-fluoro-5-phenyl-1,3-oxazol-2-yl)ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(O1)=NC(F)=C1C1=CC=CC=C1 FROMKVSMGOVTQO-UHFFFAOYSA-N 0.000 claims description 3
• ZHNRNEWWVPYTBI-UHFFFAOYSA-N 2-[2-[3-fluoro-5-(2h-tetrazol-5-yl)phenyl]ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(C=1)=CC(F)=CC=1C1=NN=NN1 ZHNRNEWWVPYTBI-UHFFFAOYSA-N 0.000 claims description 3
• 208000008811 Agoraphobia Diseases 0.000 claims description 3
• 206010012218 Delirium Diseases 0.000 claims description 3
• 208000024254 Delusional disease Diseases 0.000 claims description 3
• 208000011688 Generalised anxiety disease Diseases 0.000 claims description 3
• DWSMCWUEZIVSGM-UHFFFAOYSA-N O=C1C=2C=CC(=NC2CCC1)C#CC=1C=C(C#N)C=CC1.BrC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O.ClC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O Chemical compound O=C1C=2C=CC(=NC2CCC1)C#CC=1C=C(C#N)C=CC1.BrC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O.ClC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O DWSMCWUEZIVSGM-UHFFFAOYSA-N 0.000 claims description 3
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
• 208000020186 Schizophreniform disease Diseases 0.000 claims description 3
• 206010041250 Social phobia Diseases 0.000 claims description 3
• 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 3
• 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 3
• 208000029364 generalized anxiety disease Diseases 0.000 claims description 3
• 208000002851 paranoid schizophrenia Diseases 0.000 claims description 3
• 208000022610 schizoaffective disease Diseases 0.000 claims description 3
• QMEDLAZYJXJINI-UHFFFAOYSA-N 2-[2-(1,3,4-oxadiazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=NN=CO1 QMEDLAZYJXJINI-UHFFFAOYSA-N 0.000 claims description 2
• IICLTQRYRFSOHN-UHFFFAOYSA-N 2-[2-(1,3,4-thiadiazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=NN=CS1 IICLTQRYRFSOHN-UHFFFAOYSA-N 0.000 claims description 2
• GTVYIZYSMKVYAN-UHFFFAOYSA-N 2-[2-(1,3-oxazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=NC=CO1 GTVYIZYSMKVYAN-UHFFFAOYSA-N 0.000 claims description 2
• SDATUZQSEBHCAT-UHFFFAOYSA-N 2-[2-(1,3-thiazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=NC=CS1 SDATUZQSEBHCAT-UHFFFAOYSA-N 0.000 claims description 2
• OWGWDIPIBGISDF-UHFFFAOYSA-N 2-[2-(2h-tetrazol-5-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=NN=NN1 OWGWDIPIBGISDF-UHFFFAOYSA-N 0.000 claims description 2
• ZJFXBSKAHWJPQZ-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC=CC(Cl)=C1 ZJFXBSKAHWJPQZ-UHFFFAOYSA-N 0.000 claims description 2
• YROKDIOYNZGTMR-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC=CC(F)=C1 YROKDIOYNZGTMR-UHFFFAOYSA-N 0.000 claims description 2
• CBNSFYLAWVPDRL-UHFFFAOYSA-N 2-[2-(3-hydroxyphenyl)ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC=CC(O)=C1 CBNSFYLAWVPDRL-UHFFFAOYSA-N 0.000 claims description 2
• JDIXSWRJKJTBQM-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound COC1=CC=CC(C#CC=2N=C3CCC(C)(C)C(=O)C3=CC=2)=C1 JDIXSWRJKJTBQM-UHFFFAOYSA-N 0.000 claims description 2
• AZKTVIVFHLROFO-UHFFFAOYSA-N 2-[2-(3-morpholin-4-ylphenyl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC(C=1)=CC=CC=1N1CCOCC1 AZKTVIVFHLROFO-UHFFFAOYSA-N 0.000 claims description 2
• OITQDLHYNQRPRB-UHFFFAOYSA-N 2-[2-(3-piperidin-1-ylphenyl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC(C=1)=CC=CC=1N1CCCCC1 OITQDLHYNQRPRB-UHFFFAOYSA-N 0.000 claims description 2
• ZAXLDSKNHMSKRK-UHFFFAOYSA-N 2-[2-(4-fluoro-1,3-thiazol-2-yl)ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=NC(F)=CS1 ZAXLDSKNHMSKRK-UHFFFAOYSA-N 0.000 claims description 2
• NCVSLGBLKWNHLV-UHFFFAOYSA-N 2-[2-(4-fluoro-1,3-thiazol-2-yl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=NC(F)=CS1 NCVSLGBLKWNHLV-UHFFFAOYSA-N 0.000 claims description 2
• OOFMUMZAPXWITE-UHFFFAOYSA-N 2-[2-(4-fluoro-1,3-thiazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound FC1=CSC(C#CC=2N=C3CCCC(=O)C3=CC=2)=N1 OOFMUMZAPXWITE-UHFFFAOYSA-N 0.000 claims description 2
• BWGWYDSIQPZDKD-UHFFFAOYSA-N 2-[2-(4-fluoro-5-phenyl-1,3-oxazol-2-yl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(O1)=NC(F)=C1C1=CC=CC=C1 BWGWYDSIQPZDKD-UHFFFAOYSA-N 0.000 claims description 2
• SNYQZNDOGIICSY-UHFFFAOYSA-N 2-[2-(4-fluoro-5-phenyl-1,3-oxazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound FC=1N=C(C#CC=2N=C3CCCC(=O)C3=CC=2)OC=1C1=CC=CC=C1 SNYQZNDOGIICSY-UHFFFAOYSA-N 0.000 claims description 2
• YEPFXYBCNJHGBW-UHFFFAOYSA-N 2-[2-(4-fluoro-5-pyridin-3-yl-1,3-oxazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound FC=1N=C(C#CC=2N=C3CCCC(=O)C3=CC=2)OC=1C1=CC=CN=C1 YEPFXYBCNJHGBW-UHFFFAOYSA-N 0.000 claims description 2
• DRUIJYXGFFBRBC-UHFFFAOYSA-N 2-[2-(4-methyl-1,3-thiazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound CC1=CSC(C#CC=2N=C3CCCC(=O)C3=CC=2)=N1 DRUIJYXGFFBRBC-UHFFFAOYSA-N 0.000 claims description 2
• MXWWDEHODQJOPC-UHFFFAOYSA-N 2-[2-(4-pyridin-3-ylimidazol-1-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CN(C=1)C=NC=1C1=CC=CN=C1 MXWWDEHODQJOPC-UHFFFAOYSA-N 0.000 claims description 2
• JFVLLWVVCVZJEB-UHFFFAOYSA-N 2-[2-(5-fluoropyridin-3-yl)ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CN=CC(F)=C1 JFVLLWVVCVZJEB-UHFFFAOYSA-N 0.000 claims description 2
• INQQUKOXPFGNMR-UHFFFAOYSA-N 2-[2-(5-fluoropyridin-3-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound FC1=CN=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=C1 INQQUKOXPFGNMR-UHFFFAOYSA-N 0.000 claims description 2
• IXBICUAVAQGWNU-UHFFFAOYSA-N 2-[2-(5-pyridin-3-yl-1,3,4-oxadiazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC(O1)=NN=C1C1=CC=CN=C1 IXBICUAVAQGWNU-UHFFFAOYSA-N 0.000 claims description 2
• FWODNWAHWLOHFJ-UHFFFAOYSA-N 2-[2-[3-(2h-tetrazol-5-yl)phenyl]ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC(C=1)=CC=CC=1C1=NN=NN1 FWODNWAHWLOHFJ-UHFFFAOYSA-N 0.000 claims description 2
• PBTQOURWRZEBGL-UHFFFAOYSA-N 2-[2-[3-(trifluoromethyl)phenyl]ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound FC(F)(F)C1=CC=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=C1 PBTQOURWRZEBGL-UHFFFAOYSA-N 0.000 claims description 2
• NFSZSPZJJGBLNO-UHFFFAOYSA-N 2-[2-[3-fluoro-5-(2h-tetrazol-5-yl)phenyl]ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(C=1)=CC(F)=CC=1C1=NN=NN1 NFSZSPZJJGBLNO-UHFFFAOYSA-N 0.000 claims description 2
• ZQZGTRYXRHHYCE-UHFFFAOYSA-N 2-[2-[3-fluoro-5-(2h-tetrazol-5-yl)phenyl]ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C(F)=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=CC=1C1=NN=NN1 ZQZGTRYXRHHYCE-UHFFFAOYSA-N 0.000 claims description 2
• ABWAVQDKAUXLIW-UHFFFAOYSA-N 3-[2-(6,6-dimethyl-5-oxo-7,8-dihydroquinolin-2-yl)ethynyl]-5-fluorobenzonitrile Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC(F)=CC(C#N)=C1 ABWAVQDKAUXLIW-UHFFFAOYSA-N 0.000 claims description 2
• GVXUHRJXFKDNHS-UHFFFAOYSA-N 3-[2-(6,6-dimethyl-5-oxo-7,8-dihydroquinolin-2-yl)ethynyl]benzonitrile Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC=CC(C#N)=C1 GVXUHRJXFKDNHS-UHFFFAOYSA-N 0.000 claims description 2
• NCKVXFPPXJHMGU-UHFFFAOYSA-N 3-[2-(7,7-dimethyl-5-oxo-6,8-dihydroquinolin-2-yl)ethynyl]-5-fluorobenzonitrile Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC(F)=CC(C#N)=C1 NCKVXFPPXJHMGU-UHFFFAOYSA-N 0.000 claims description 2
• BBZHWYSWPNSPBT-UHFFFAOYSA-N 3-fluoro-5-[2-(5-oxo-7,8-dihydro-6h-quinolin-2-yl)ethynyl]benzonitrile Chemical compound FC1=CC(C#N)=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=C1 BBZHWYSWPNSPBT-UHFFFAOYSA-N 0.000 claims description 2
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
• GXHZJFOEDFUGMK-UHFFFAOYSA-N 6,6-dimethyl-2-(2-phenylethynyl)-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC=CC=C1 GXHZJFOEDFUGMK-UHFFFAOYSA-N 0.000 claims description 2
• LDYGMFKOIUCKQE-UHFFFAOYSA-N 6,6-dimethyl-2-(2-pyridin-3-ylethynyl)-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC=CN=C1 LDYGMFKOIUCKQE-UHFFFAOYSA-N 0.000 claims description 2
• VYICLAZYRGQYIF-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(1,3,4-thiadiazol-2-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=NN=CS1 VYICLAZYRGQYIF-UHFFFAOYSA-N 0.000 claims description 2
• IOZMODDHDZWFGN-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(1,3-oxazol-2-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=NC=CO1 IOZMODDHDZWFGN-UHFFFAOYSA-N 0.000 claims description 2
• QJRCANJKXZGTHY-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(1,3-oxazol-5-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CN=CO1 QJRCANJKXZGTHY-UHFFFAOYSA-N 0.000 claims description 2
• JZIVAYZVDUEZSY-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(1,3-thiazol-5-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CN=CS1 JZIVAYZVDUEZSY-UHFFFAOYSA-N 0.000 claims description 2
• XAKZHHCPPPMPPS-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(2-phenyl-1,3-oxazol-5-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(O1)=CN=C1C1=CC=CC=C1 XAKZHHCPPPMPPS-UHFFFAOYSA-N 0.000 claims description 2
• AMLRWFNLPASRFE-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(2h-tetrazol-5-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=NN=NN1 AMLRWFNLPASRFE-UHFFFAOYSA-N 0.000 claims description 2
• HDXVYHYLTWAPFA-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(3-methylphenyl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound CC1=CC=CC(C#CC=2N=C3CCC(C)(C)C(=O)C3=CC=2)=C1 HDXVYHYLTWAPFA-UHFFFAOYSA-N 0.000 claims description 2
• XXERCQMVCRFKDQ-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(3-morpholin-4-ylphenyl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(C=1)=CC=CC=1N1CCOCC1 XXERCQMVCRFKDQ-UHFFFAOYSA-N 0.000 claims description 2
• CEQVBRIWEBJPQC-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(4-methyl-1,3-oxazol-2-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound CC1=COC(C#CC=2N=C3CCC(C)(C)C(=O)C3=CC=2)=N1 CEQVBRIWEBJPQC-UHFFFAOYSA-N 0.000 claims description 2
• IUYLVWZROBHOCY-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(4-methyl-1,3-thiazol-2-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound CC1=CSC(C#CC=2N=C3CCC(C)(C)C(=O)C3=CC=2)=N1 IUYLVWZROBHOCY-UHFFFAOYSA-N 0.000 claims description 2
• YKQBFJKVSFWJDQ-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(5-phenyl-1,3-thiazol-2-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(S1)=NC=C1C1=CC=CC=C1 YKQBFJKVSFWJDQ-UHFFFAOYSA-N 0.000 claims description 2
• CXOGWLXMJACMQB-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(5-pyridin-3-yl-1,3,4-oxadiazol-2-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(O1)=NN=C1C1=CC=CN=C1 CXOGWLXMJACMQB-UHFFFAOYSA-N 0.000 claims description 2
• DPKFIBNTOFXZFE-UHFFFAOYSA-N 6,6-dimethyl-2-[2-[3-(2h-tetrazol-5-yl)phenyl]ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(C=1)=CC=CC=1C1=NN=NN1 DPKFIBNTOFXZFE-UHFFFAOYSA-N 0.000 claims description 2
• DLOKZVHUFIKFCS-UHFFFAOYSA-N 6,6-dimethyl-2-[2-[3-(trifluoromethyl)phenyl]ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC=CC(C(F)(F)F)=C1 DLOKZVHUFIKFCS-UHFFFAOYSA-N 0.000 claims description 2
• OUIAOAZNGDRWKB-UHFFFAOYSA-N 7,7-dimethyl-2-(2-phenylethynyl)-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CC=C1 OUIAOAZNGDRWKB-UHFFFAOYSA-N 0.000 claims description 2
• PYEJMMIENZLMLY-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(1,3,4-thiadiazol-2-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=NN=CS1 PYEJMMIENZLMLY-UHFFFAOYSA-N 0.000 claims description 2
• UFDZJSUPEGYOSB-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(1,3-oxazol-2-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=NC=CO1 UFDZJSUPEGYOSB-UHFFFAOYSA-N 0.000 claims description 2
• AMDRFLRNDXPXIX-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(2-phenyl-1,3-oxazol-5-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(O1)=CN=C1C1=CC=CC=C1 AMDRFLRNDXPXIX-UHFFFAOYSA-N 0.000 claims description 2
• DNEZVKIAGDJZIU-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(2h-tetrazol-5-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=NN=NN1 DNEZVKIAGDJZIU-UHFFFAOYSA-N 0.000 claims description 2
• BBKKMYAZVZPOJE-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(3-morpholin-4-ylphenyl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(C=1)=CC=CC=1N1CCOCC1 BBKKMYAZVZPOJE-UHFFFAOYSA-N 0.000 claims description 2
• ZREKYIVLYQCSTH-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(3-piperidin-1-ylphenyl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(C=1)=CC=CC=1N1CCCCC1 ZREKYIVLYQCSTH-UHFFFAOYSA-N 0.000 claims description 2
• UIJHHZTYUUIANC-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(4-methyl-1,3-thiazol-2-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound CC1=CSC(C#CC=2N=C3CC(C)(C)CC(=O)C3=CC=2)=N1 UIJHHZTYUUIANC-UHFFFAOYSA-N 0.000 claims description 2
• QOMRJFCJOXWHRJ-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(4-pyridin-3-ylimidazol-1-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CN(C=1)C=NC=1C1=CC=CN=C1 QOMRJFCJOXWHRJ-UHFFFAOYSA-N 0.000 claims description 2
• ZWIBSURIOBYIHL-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(5-phenyl-1,3-thiazol-2-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(S1)=NC=C1C1=CC=CC=C1 ZWIBSURIOBYIHL-UHFFFAOYSA-N 0.000 claims description 2
• JQQFWFZGJCFHIS-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(5-pyridin-3-yl-1,3,4-oxadiazol-2-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(O1)=NN=C1C1=CC=CN=C1 JQQFWFZGJCFHIS-UHFFFAOYSA-N 0.000 claims description 2
• CFCFZUBDICQZNZ-UHFFFAOYSA-N 7,7-dimethyl-2-[2-[3-(2h-tetrazol-5-yl)phenyl]ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(C=1)=CC=CC=1C1=NN=NN1 CFCFZUBDICQZNZ-UHFFFAOYSA-N 0.000 claims description 2
• DEFUPEBZAMTQIL-UHFFFAOYSA-N 7,7-dimethyl-2-[2-[3-(trifluoromethyl)phenyl]ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CC(C(F)(F)F)=C1 DEFUPEBZAMTQIL-UHFFFAOYSA-N 0.000 claims description 2
• 150000002431 hydrogen Chemical class 0.000 claims description 2
• 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims description 2
• 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims description 2
• 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 4
• MTZVCTXZYVKFME-UHFFFAOYSA-N 2-[2-(4-fluoro-5-pyridin-3-yl-1,3-oxazol-2-yl)ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(O1)=NC(F)=C1C1=CC=CN=C1 MTZVCTXZYVKFME-UHFFFAOYSA-N 0.000 claims 1
• CRBSEKHHCGSYNJ-UHFFFAOYSA-N 2-[2-(5-fluoro-4-pyridin-3-yl-1h-imidazol-2-yl)ethynyl]-6,6-dimethyl-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(N1)=NC(F)=C1C1=CC=CN=C1 CRBSEKHHCGSYNJ-UHFFFAOYSA-N 0.000 claims 1
• PDUGLNOMNQIHRJ-UHFFFAOYSA-N 2-[2-(5-fluoro-4-pyridin-3-yl-1h-imidazol-2-yl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC(N1)=NC(F)=C1C1=CC=CN=C1 PDUGLNOMNQIHRJ-UHFFFAOYSA-N 0.000 claims 1
• YHQVRLXCYVDYPN-UHFFFAOYSA-N 2-[2-(5-fluoro-4-pyridin-3-yl-1h-imidazol-2-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound FC=1N=C(C#CC=2N=C3CCCC(=O)C3=CC=2)NC=1C1=CC=CN=C1 YHQVRLXCYVDYPN-UHFFFAOYSA-N 0.000 claims 1
• HOCSKZAWHBVORN-UHFFFAOYSA-N 2-[2-(5-fluoropyridin-3-yl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CN=CC(F)=C1 HOCSKZAWHBVORN-UHFFFAOYSA-N 0.000 claims 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
• JISHVWJTNYBJLA-UHFFFAOYSA-N 6,6-dimethyl-2-(2-pyridin-2-ylethynyl)-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC=CC=N1 JISHVWJTNYBJLA-UHFFFAOYSA-N 0.000 claims 1
• YOPWWRTVTMSADT-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(3-piperidin-1-ylphenyl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC(C=1)=CC=CC=1N1CCCCC1 YOPWWRTVTMSADT-UHFFFAOYSA-N 0.000 claims 1
• OQENHVJJOAGGHC-UHFFFAOYSA-N 6,6-dimethyl-2-[2-(4-pyridin-3-ylimidazol-1-yl)ethynyl]-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CN(C=1)C=NC=1C1=CC=CN=C1 OQENHVJJOAGGHC-UHFFFAOYSA-N 0.000 claims 1
• SCPSZEPCKKTLAC-UHFFFAOYSA-N 7,7-dimethyl-2-(2-pyridin-2-ylethynyl)-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CC=N1 SCPSZEPCKKTLAC-UHFFFAOYSA-N 0.000 claims 1
• UUCDLNBJJHRIOP-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(4-methyl-1,3-oxazol-2-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound CC1=COC(C#CC=2N=C3CC(C)(C)CC(=O)C3=CC=2)=N1 UUCDLNBJJHRIOP-UHFFFAOYSA-N 0.000 claims 1
• 238000002360 preparation method Methods 0.000 abstract description 136
• 238000000034 method Methods 0.000 abstract description 123
• 230000008569 process Effects 0.000 abstract description 3
• 208000012902 Nervous system disease Diseases 0.000 abstract description 2
• 208000025966 Neurological disease Diseases 0.000 abstract description 2
• 239000000203 mixture Substances 0.000 description 42
• 238000009472 formulation Methods 0.000 description 21
• 239000000243 solution Substances 0.000 description 16
• 239000007788 liquid Substances 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
• 102000005962 receptors Human genes 0.000 description 13
• 108020003175 receptors Proteins 0.000 description 13
• 239000003826 tablet Substances 0.000 description 12
• 230000000694 effects Effects 0.000 description 11
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 11
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 239000002775 capsule Substances 0.000 description 9
• 235000019441 ethanol Nutrition 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 125000000217 alkyl group Chemical group 0.000 description 8
• 229930195712 glutamate Natural products 0.000 description 8
• 229940049906 glutamate Drugs 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
• 210000001130 astrocyte Anatomy 0.000 description 7
• 239000003085 diluting agent Substances 0.000 description 7
• NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 6
• 239000005695 Ammonium acetate Substances 0.000 description 6
• 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 6
• 230000002159 abnormal effect Effects 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 239000000443 aerosol Substances 0.000 description 6
• 235000019257 ammonium acetate Nutrition 0.000 description 6
• 229940043376 ammonium acetate Drugs 0.000 description 6
• 239000011575 calcium Substances 0.000 description 6
• 229910052791 calcium Inorganic materials 0.000 description 6
• 125000004432 carbon atom Chemical group C* 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• 210000003169 central nervous system Anatomy 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
• 229930006000 Sucrose Natural products 0.000 description 5
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
• 150000007513 acids Chemical class 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 210000004027 cell Anatomy 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 102000004169 proteins and genes Human genes 0.000 description 5
• 108090000623 proteins and genes Proteins 0.000 description 5
• 239000008213 purified water Substances 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 229960004793 sucrose Drugs 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 230000005062 synaptic transmission Effects 0.000 description 5
• 239000003981 vehicle Substances 0.000 description 5
• MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000002858 neurotransmitter agent Substances 0.000 description 4
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
• 239000000829 suppository Substances 0.000 description 4
• 239000000454 talc Substances 0.000 description 4
• 235000012222 talc Nutrition 0.000 description 4
• 229910052623 talc Inorganic materials 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 229920000954 Polyglycolide Polymers 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 230000008499 blood brain barrier function Effects 0.000 description 3
• 210000001218 blood-brain barrier Anatomy 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 208000015114 central nervous system disease Diseases 0.000 description 3
• 230000001054 cortical effect Effects 0.000 description 3
• 235000013681 dietary sucrose Nutrition 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 229960000367 inositol Drugs 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 229940016286 microcrystalline cellulose Drugs 0.000 description 3
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
• 239000008108 microcrystalline cellulose Substances 0.000 description 3
• 239000002105 nanoparticle Substances 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000004633 polyglycolic acid Substances 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 235000010356 sorbitol Nutrition 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• XOUDFZJCSDKXLG-UHFFFAOYSA-N 2-(2-phenylethynyl)-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=CC=CC=C1 XOUDFZJCSDKXLG-UHFFFAOYSA-N 0.000 description 2
• AXZZTESGQIARIE-UHFFFAOYSA-N 2-(2-pyridin-3-ylethynyl)-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=CC=CN=C1 AXZZTESGQIARIE-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• YMMHAIJRFWRDMG-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-1h-quinolin-2-one Chemical group C1C=CC=C2NC(=O)CCC21 YMMHAIJRFWRDMG-UHFFFAOYSA-N 0.000 description 2
• ZKOPJTIDGYUNFS-UHFFFAOYSA-N 3-[2-(7,7-dimethyl-5-oxo-6,8-dihydroquinolin-2-yl)ethynyl]benzonitrile Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CC(C#N)=C1 ZKOPJTIDGYUNFS-UHFFFAOYSA-N 0.000 description 2
• MTZNODTZOSBYJW-UHFFFAOYSA-N 3-amino-5,5-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CC(N)=CC(=O)C1 MTZNODTZOSBYJW-UHFFFAOYSA-N 0.000 description 2
• SZTYOBVVBFZNGB-UHFFFAOYSA-N 3-amino-6,6-dimethylcyclohex-2-en-1-one Chemical compound CC1(C)CCC(N)=CC1=O SZTYOBVVBFZNGB-UHFFFAOYSA-N 0.000 description 2
• CUKKWDJHTBEBML-UHFFFAOYSA-N 3-amino-6-ethyl-6-methylcyclohex-2-en-1-one Chemical compound CCC1(C)CCC(N)=CC1=O CUKKWDJHTBEBML-UHFFFAOYSA-N 0.000 description 2
• PZYNNJCKOOYBPK-UHFFFAOYSA-N 7,7-dimethyl-2-(2-pyridin-3-ylethynyl)-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CN=C1 PZYNNJCKOOYBPK-UHFFFAOYSA-N 0.000 description 2
• SSJBKGDLBXMVBQ-UHFFFAOYSA-N 7,7-dimethyl-6,8-dihydro-1h-quinoline-2,5-dione Chemical compound C1=CC(=O)NC2=C1C(=O)CC(C)(C)C2 SSJBKGDLBXMVBQ-UHFFFAOYSA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
• HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 2
• UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical compound C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
• 230000005526 G1 to G0 transition Effects 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 229910002092 carbon dioxide Inorganic materials 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 235000019700 dicalcium phosphate Nutrition 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000011888 foil Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
• 238000012744 immunostaining Methods 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 150000002916 oxazoles Chemical class 0.000 description 2
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 239000004626 polylactic acid Substances 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
• 238000010956 selective crystallization Methods 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 239000002511 suppository base Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000007916 tablet composition Substances 0.000 description 2
• 238000010998 test method Methods 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 229940098465 tincture Drugs 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 239000002691 unilamellar liposome Substances 0.000 description 2
• 0 *C(*)(Cc1c2ccc(C#C*)n1)C(*)(*)C2=O Chemical compound *C(*)(Cc1c2ccc(C#C*)n1)C(*)(*)C2=O 0.000 description 1
• LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• BGNVLXITFATMRI-UHFFFAOYSA-N 2-[2-(1,3-oxazol-5-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=CN=CO1 BGNVLXITFATMRI-UHFFFAOYSA-N 0.000 description 1
• FJLXTTKNVSGISC-UHFFFAOYSA-N 2-[2-(1,3-thiazol-5-yl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=CN=CS1 FJLXTTKNVSGISC-UHFFFAOYSA-N 0.000 description 1
• YLOVUQYISJABNR-UHFFFAOYSA-N 2-[2-(3-bromophenyl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CC(Br)=C1 YLOVUQYISJABNR-UHFFFAOYSA-N 0.000 description 1
• PPFBIVPYPBRRLN-UHFFFAOYSA-N 2-[2-(3-bromophenyl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound BrC1=CC=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=C1 PPFBIVPYPBRRLN-UHFFFAOYSA-N 0.000 description 1
• BTACZNOVTHDNPY-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CC(Cl)=C1 BTACZNOVTHDNPY-UHFFFAOYSA-N 0.000 description 1
• JRJHAUSKFDKMRR-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound ClC1=CC=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=C1 JRJHAUSKFDKMRR-UHFFFAOYSA-N 0.000 description 1
• WGRWQWKSJSXINN-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CC(F)=C1 WGRWQWKSJSXINN-UHFFFAOYSA-N 0.000 description 1
• XNJXPAACRCLMOS-UHFFFAOYSA-N 2-[2-(3-fluorophenyl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound FC1=CC=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=C1 XNJXPAACRCLMOS-UHFFFAOYSA-N 0.000 description 1
• ZINAKIAGFBYZIY-UHFFFAOYSA-N 2-[2-(3-hydroxyphenyl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CC=CC(O)=C1 ZINAKIAGFBYZIY-UHFFFAOYSA-N 0.000 description 1
• RABDJGXHQUBGBD-UHFFFAOYSA-N 2-[2-(3-hydroxyphenyl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound OC1=CC=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=C1 RABDJGXHQUBGBD-UHFFFAOYSA-N 0.000 description 1
• HMXWQKHLYGCBHC-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)ethynyl]-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound COC1=CC=CC(C#CC=2N=C3CC(C)(C)CC(=O)C3=CC=2)=C1 HMXWQKHLYGCBHC-UHFFFAOYSA-N 0.000 description 1
• PSUVVQBHUILGFV-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound COC1=CC=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=C1 PSUVVQBHUILGFV-UHFFFAOYSA-N 0.000 description 1
• CKSAEHUBBBVNEC-UHFFFAOYSA-N 2-[2-(3-methylphenyl)ethynyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound CC1=CC=CC(C#CC=2N=C3CCCC(=O)C3=CC=2)=C1 CKSAEHUBBBVNEC-UHFFFAOYSA-N 0.000 description 1
• SROAFDPESDGHPQ-UHFFFAOYSA-N 2-chloro-7,7-dimethyl-6,8-dihydroquinolin-5-one Chemical compound C1=C(Cl)N=C2CC(C)(C)CC(=O)C2=C1 SROAFDPESDGHPQ-UHFFFAOYSA-N 0.000 description 1
• GWDDFDLEOYOZLY-UHFFFAOYSA-N 2-chloro-7,8-dihydro-6h-quinolin-5-one Chemical compound O=C1CCCC2=NC(Cl)=CC=C21 GWDDFDLEOYOZLY-UHFFFAOYSA-N 0.000 description 1
• LBHZZGWMIBHNGM-UHFFFAOYSA-N 3-[2-(5-oxo-7,8-dihydro-6h-quinolin-2-yl)ethynyl]benzonitrile Chemical compound C=1C=C2C(=O)CCCC2=NC=1C#CC1=CC=CC(C#N)=C1 LBHZZGWMIBHNGM-UHFFFAOYSA-N 0.000 description 1
• PEEVKEANQYJGBI-UHFFFAOYSA-N 3-amino-5-ethylcyclohex-2-en-1-one Chemical compound CCC1CC(N)=CC(=O)C1 PEEVKEANQYJGBI-UHFFFAOYSA-N 0.000 description 1
• KHPFMSNFDYZATO-UHFFFAOYSA-N 3-amino-5-propan-2-ylcyclohex-2-en-1-one Chemical compound CC(C)C1CC(N)=CC(=O)C1 KHPFMSNFDYZATO-UHFFFAOYSA-N 0.000 description 1
• ZZMRPOAHZITKBV-UHFFFAOYSA-N 3-aminocyclohex-2-en-1-one Chemical class NC1=CC(=O)CCC1 ZZMRPOAHZITKBV-UHFFFAOYSA-N 0.000 description 1
• PLGPBTCNKJQJHQ-UHFFFAOYSA-N 4,4-dimethylcyclohexane-1,3-dione Chemical compound CC1(C)CCC(=O)CC1=O PLGPBTCNKJQJHQ-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• WWLVJBISOZBFCG-UHFFFAOYSA-N 4-propylcyclohexane-1,3-dione Chemical compound CCCC1CCC(=O)CC1=O WWLVJBISOZBFCG-UHFFFAOYSA-N 0.000 description 1
• VPRYSOJVBSTQKE-UHFFFAOYSA-N 5-ethylcyclohexane-1,3-dione Chemical compound CCC1CC(=O)CC(=O)C1 VPRYSOJVBSTQKE-UHFFFAOYSA-N 0.000 description 1
• DUKZQEYDAFUJMK-UHFFFAOYSA-N 5-propan-2-ylcyclohexane-1,3-dione Chemical compound CC(C)C1CC(=O)CC(=O)C1 DUKZQEYDAFUJMK-UHFFFAOYSA-N 0.000 description 1
• WIBKUHFGXOTKQF-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(1,3-oxazol-5-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CN=CO1 WIBKUHFGXOTKQF-UHFFFAOYSA-N 0.000 description 1
• RTYQYCCAVPFDFK-UHFFFAOYSA-N 7,7-dimethyl-2-[2-(1,3-thiazol-5-yl)ethynyl]-6,8-dihydroquinolin-5-one Chemical compound N1=C2CC(C)(C)CC(=O)C2=CC=C1C#CC1=CN=CS1 RTYQYCCAVPFDFK-UHFFFAOYSA-N 0.000 description 1
• YHHBKPWMEXGLKE-UHFFFAOYSA-N 7,8-dihydro-6h-quinolin-5-one Chemical compound C1=CC=C2C(=O)CCCC2=N1 YHHBKPWMEXGLKE-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 235000019489 Almond oil Nutrition 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 238000012371 Aseptic Filling Methods 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• KDASLYNVNATGGK-UHFFFAOYSA-N BrC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O.ClC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O Chemical compound BrC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O.ClC=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O KDASLYNVNATGGK-UHFFFAOYSA-N 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• VOFPQPUDKKDYFH-UHFFFAOYSA-N CC1(C(C=2C=CC(=NC2CC1)C#CC1=CC(=CC=C1)N1CCCCC1)=O)C.CC1(C(C=2C=CC(=NC2CC1)C#CC1=CN=CS1)=O)C Chemical compound CC1(C(C=2C=CC(=NC2CC1)C#CC1=CC(=CC=C1)N1CCCCC1)=O)C.CC1(C(C=2C=CC(=NC2CC1)C#CC1=CN=CS1)=O)C VOFPQPUDKKDYFH-UHFFFAOYSA-N 0.000 description 1
• ZIDHZOHEVXQHOW-UHFFFAOYSA-N CC1(CC(C=2C=CC(=NC2C1)C#CC1=CC(=CC=C1)N1CCOCC1)=O)C.N1(CCOCC1)C=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O Chemical compound CC1(CC(C=2C=CC(=NC2C1)C#CC1=CC(=CC=C1)N1CCOCC1)=O)C.N1(CCOCC1)C=1C=C(C=CC1)C#CC1=NC=2CCCC(C2C=C1)=O ZIDHZOHEVXQHOW-UHFFFAOYSA-N 0.000 description 1
• DHVURHNGTQBPOD-UHFFFAOYSA-N COC=1C=C(C=CC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C.ClC=1C=C(C=CC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C Chemical compound COC=1C=C(C=CC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C.ClC=1C=C(C=CC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C DHVURHNGTQBPOD-UHFFFAOYSA-N 0.000 description 1
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 244000183685 Citrus aurantium Species 0.000 description 1
• 235000007716 Citrus aurantium Nutrition 0.000 description 1
• 240000002319 Citrus sinensis Species 0.000 description 1
• 235000005976 Citrus sinensis Nutrition 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• HTJVLWNJJHFHGB-UHFFFAOYSA-N FC=1C=C(C#N)C=C(C1)C#CC1=NC=2CCCC(C2C=C1)=O.FC=1C=C(C=NC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C Chemical compound FC=1C=C(C#N)C=C(C1)C#CC1=NC=2CCCC(C2C=C1)=O.FC=1C=C(C=NC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C HTJVLWNJJHFHGB-UHFFFAOYSA-N 0.000 description 1
• AIVSJAANWFYILE-UHFFFAOYSA-N FC=1C=C(C=CC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C.CC1(C(C=2C=CC(=NC2CC1)C#CC=1C=NC=CC1)=O)C Chemical compound FC=1C=C(C=CC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C.CC1(C(C=2C=CC(=NC2CC1)C#CC=1C=NC=CC1)=O)C AIVSJAANWFYILE-UHFFFAOYSA-N 0.000 description 1
• TUYVNERHNKDDJC-UHFFFAOYSA-N FC=1C=C(C=NC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C.CC1(C(C=2C=CC(=NC2CC1)C#CC=1SC(=CN1)C1=CC=CC=C1)=O)C Chemical compound FC=1C=C(C=NC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C.CC1(C(C=2C=CC(=NC2CC1)C#CC=1SC(=CN1)C1=CC=CC=C1)=O)C TUYVNERHNKDDJC-UHFFFAOYSA-N 0.000 description 1
• JRPYGYNWEHVAOP-UHFFFAOYSA-N FC=1C=C(C=NC1)C#CC1=NC=2CCCC(C2C=C1)=O.C1(=CC=CC=C1)C=1SC(=CN1)C#CC1=NC=2CCCC(C2C=C1)=O Chemical compound FC=1C=C(C=NC1)C#CC1=NC=2CCCC(C2C=C1)=O.C1(=CC=CC=C1)C=1SC(=CN1)C#CC1=NC=2CCCC(C2C=C1)=O JRPYGYNWEHVAOP-UHFFFAOYSA-N 0.000 description 1
• YTVPEWMXLGCJGF-UHFFFAOYSA-N FC=1N=C(SC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C.FC=1N=C(SC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C Chemical compound FC=1N=C(SC1)C#CC1=NC=2CCC(C(C2C=C1)=O)(C)C.FC=1N=C(SC1)C#CC1=NC=2CC(CC(C2C=C1)=O)(C)C YTVPEWMXLGCJGF-UHFFFAOYSA-N 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 239000012586 G-5 Supplement Substances 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
• 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 1
• 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
• 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 1
• 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 description 1
• 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 1
• 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 1
• BJJBLXPHATYXSL-UHFFFAOYSA-N N1=CC(=CC=C1)C1=NN=C(O1)C#CC1=NC=2CCCC(C2C=C1)=O.CC1(CC(C=2C=CC(=NC2C1)C#CC=1OC(=NN1)C=1C=NC=CC1)=O)C Chemical compound N1=CC(=CC=C1)C1=NN=C(O1)C#CC1=NC=2CCCC(C2C=C1)=O.CC1(CC(C=2C=CC(=NC2C1)C#CC=1OC(=NN1)C=1C=NC=CC1)=O)C BJJBLXPHATYXSL-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 239000004141 Sodium laurylsulphate Substances 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 239000004809 Teflon Substances 0.000 description 1
• 229920006362 Teflon® Polymers 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000000475 acetylene derivatives Chemical class 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 230000003281 allosteric effect Effects 0.000 description 1
• 239000008168 almond oil Substances 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 230000003140 astrocytic effect Effects 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 150000001538 azepines Chemical class 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 230000027455 binding Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000012742 biochemical analysis Methods 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 239000000337 buffer salt Substances 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229940003871 calcium ion Drugs 0.000 description 1
• 229910001424 calcium ion Inorganic materials 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 229940078456 calcium stearate Drugs 0.000 description 1
• 235000011132 calcium sulphate Nutrition 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 239000007963 capsule composition Substances 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 229960004106 citric acid Drugs 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• HJSLFCCWAKVHIW-UHFFFAOYSA-N cyclohexane-1,3-dione Chemical class O=C1CCCC(=O)C1 HJSLFCCWAKVHIW-UHFFFAOYSA-N 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000012154 double-distilled water Substances 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000007720 emulsion polymerization reaction Methods 0.000 description 1
• JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
• 229950010048 enbucrilate Drugs 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000007888 film coating Substances 0.000 description 1
• 238000009501 film coating Methods 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 150000002240 furans Chemical class 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 229940049654 glyceryl behenate Drugs 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 229960003943 hypromellose Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• 150000002462 imidazolines Chemical class 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000011630 iodine Chemical group 0.000 description 1
• 230000001057 ionotropic effect Effects 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 150000002545 isoxazoles Chemical class 0.000 description 1
• 150000002546 isoxazolidines Chemical class 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 1
• 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
• 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 1
• 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 description 1
• 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 1
• 108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 1
• 102000006239 metabotropic receptors Human genes 0.000 description 1
• 108020004083 metabotropic receptors Proteins 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 210000000274 microglia Anatomy 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 210000000478 neocortex Anatomy 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 229940100688 oral solution Drugs 0.000 description 1
• 239000007968 orange flavor Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 150000004866 oxadiazoles Chemical class 0.000 description 1
• 150000002917 oxazolidines Chemical class 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000035778 pathophysiological process Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229960000502 poloxamer Drugs 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 229920002721 polycyanoacrylate Polymers 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 229920006324 polyoxymethylene Polymers 0.000 description 1
• 230000001242 postsynaptic effect Effects 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960004063 propylene glycol Drugs 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 150000003216 pyrazines Chemical class 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• 150000004892 pyridazines Chemical class 0.000 description 1
• 150000003222 pyridines Chemical class 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 150000003233 pyrroles Chemical class 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 210000002265 sensory receptor cell Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
• 235000010378 sodium ascorbate Nutrition 0.000 description 1
• 229960005055 sodium ascorbate Drugs 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 150000003557 thiazoles Chemical class 0.000 description 1
• 150000003548 thiazolidines Chemical class 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1